Zoey Becker/LinkedIn
Dec 11, 2025, 12:12
Zoey Becker: CSL Proves Efficacy of Hemophilia B Gene Therapy Hemgenix Holds up After 5 Years
Brian James, Chief Operating Officer at Rondaxe Pharma LLC, shared an article on LinkedIn:
“Are the new gene therapies durable? It’s nice to see a resounding “yes” like this.”
Title: ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years
Authors: Zoey Becker
Read the paper here.
Hemostasis Today: Advancing the Discourse in Thrombosis and Hemostasis.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy